The aim of the study is to explore the safety and feasibility of a Treg-based approach as an adjunct immunosuppressive treatment for HSCT recipients early after HSCT. The goal is to prevent the development of acute GvHD, to moderate the severity and to reduce the need for pharmacologic immunosuppression, most specifically the exposure towards steroids, and thus the immunosuppressive burden after HSCT, which exposes recipients to relevant morbidity and potentially
mortality.
The aim of the study is to investigate the safety and feasibility of a Treg-based approach as a complementary immunosuppressive treatment for HSCT recipients early after HSCT. The aim is to prevent the development of acute GvHD, mitigate its severity and reduce the need for pharmacologic immunosuppression, in particular steroid exposure.
